Anne-Catrin Uhlemann, MD, PhD
- Associate Professor of Medicine
Dr. Anne-Catrin Uhlemann is the Florence Irving Assistant Professor of Medicine in the Division of Infectious Diseases in the College of Physicians and Surgeons at Columbia University.
Dr. Anne-Catrin Uhlemann's laboratory investigates the evolution of bacterial pathogens such as Staphylococcus aureus and carbapenem-resistant Klebsiella pneumoniae.
Departments and Divisions
- Department of Medicine
Division of Infectious Diseases
- Infectious Disease
- Internal Medicine
Areas of Expertise
- Bacterial Infection
- Infectious Disease
- Organ Transplant Infections
- Staphylococcal Infection
Education & Training
- Eberhard-Karls University (Germany)
- Residency: NewYork-Presbyterian Hospital/Columbia University Medical Center
- Fellowship: NewYork-Presbyterian Hospital/Columbia University Medical Center
Harkness Pavilion180 Fort Washington Avenue
New York, NY 10032
- (212) 305-8039
- For new and current patient appointments, call:
- (212) 305-8039
- (212) 305-1754
Please contact the provider's office directly to verify that your particular insurance is accepted.
- Aetna [EPO, HMO, Medicare Managed Care, NY Signature, POS, PPO, Signature Administrators, Student Health]
- Cigna [EPO, Great West, HMO, POS, PPO]
- Emblem/GHI [HMO, Medicare Managed Care, PPO]
- Emblem/HIP [ConnectiCare, EPO, Essential Plan, HMO, Medicaid Managed Care, Medicare Managed Care, POS, PPO, Select Care (Exchange), Vytra]
- Empire Blue Cross Blue Shield [Blue Priority, EPO, HMO, Medicare (Mediblue), NYP Employee Plan, Pathway (Exchange), POS, PPO]
- Local 1199 [Local 1199]
- MagnaCare [MagnaCare]
- Multiplan [Multiplan]
- Oxford Health Plans [Freedom, Liberty, Medicare Managed Care]
- POMCO [POMCO]
- UnitedHealthcare [Columbia University Employee Plan, Compass (Exchange), EPO, Essential Plan, HMO, Medicaid (Community Plan), Medicare Managed Care, POS, PPO]
This provider does not accept new patients
Committees / Societies / Memberships
Member, American Society of Microbiology
Member, Infectious Diseases Society of America
Honors & Awards
2014 - 2017 Florence Irving Assistant Professor of Medicine
2010 - 2013 Paul A. Marks Scholar, Columbia University
- Bacterial evolution
- Multi-drug resistant infections
INNATE IMMUNE CLEARANCE OF HOST-ADAPTED PULMONARY PATHOGENS (Federal Gov)
Jan 11 2017 - Nov 30 2023
DEVELOPMENT AND SIGNIFICANCE OF THE PLASMA CELL NICHE IN THE HUMANINFANT THYMUS (Federal Gov)
Aug 23 2017 - Jul 31 2022
CLINICAL AND TRANSLATIONAL SCIENCE AWARD (Federal Gov)
Jul 1 2016 - May 31 2021
CARBAPENEM-RESISTANT BACTERIAL COLONIZATION AND INFECTION IN LIVER TRANSPLANT (Federal Gov)
Jan 14 2015 - Dec 31 2019
ACTIVITY OF IMIPENEM-RELEBACTAM IN DIVERSE EMERGING CRE: A COMBINED EPIDEMIOLOGICAL AND GENOMICS APPROACH (Private)
Apr 6 2016 - Apr 5 2018
MECHANISMS OF S. AUREUS TRANSMISSION AND PERSISTENCE (Federal Gov)
Jul 1 2010 - Jun 30 2016
NYPH TRANSLATIONAL GRANT SUBCONTRACT (NY State Gov)
Jul 1 2014 - Jun 30 2015
THE USE OF WHOLE GENOME SEQUENCING TO IDENTIFY SPREAD OF USA300 IN THE COMMUNITY (Federal Gov)
Feb 11 2013 - Jan 31 2015
S. aureus research: The past decade has witnessed a dramatic increase in Staphylococcus aureus infections acquired from the community. Yet there remains a limited understanding of how these strains spread and subsequently become established and persist within communities. Our research is focused on identifying molecular mechanisms that allow epidemic S. aureus strains such as USA300 to successfully disseminate. This project uses a combined approach of whole-genome comparative sequencing of longitudinally collected samples, genetic manipulation, and functional studies on bacterial adhesion and survival. These molecular studies are informed by ongoing epidemiological studies on S. aureus transmission in the local community. This work has identified a potentially newly emerging S. aureus strain, ST398, which was previously only associated with close contacts to animals. Ongoing studies are aimed at elucidating the molecular mechanisms of its cross-species transfer and current animal-independent spread.
K. pneumoniae infections in transplant recipients: Infections with carbapenem-resistant Enterobacteriaceae (CRE) have emerged as an urgent threat to healthcare, the “category of highest concern” in the 2013 CDC antimicrobial threat report. These multi-drug resistant infections are associated with high mortality. Recipients of solid organ transplantation, in particular liver transplant recipients are at increased risk for CRE infections. While intestinal colonization with CREs has been proposed as a potential risk factor for infections during CRE outbreaks, its actual contribution to infection remains incompletely understood. Moreover, there is a fundamental gap in knowledge on how these antibiotic resistant organisms transition from colonization to infection within affected hosts. We have established a cohort study of patients undergoing liver transplantation in which we aim to investigate the contribution of colonization to subsequent CRE infection. The long-term goal of this project is to elucidate at the bacterial genome level how CRE infections emerge and spread. Understanding these processes is critical to developing intervention and real-time clinical monitoring approaches to limit the impact of CRE infections at an individual and population level.
- Angela Gomez-Simmonds, MD, Fellow
- Eloise Austin, MD, Fellow
Austin ED, Sullivan SB, Whittier S, Lowy FD, Uhlemann AC. Peripheral Intravenous Catheter Placement Is an Underrecognized Source of Staphylococcus aureus Bloodstream Infection. Open Forum Infect Dis. 2016 Apr 6;3(2):ofw072. eCollection 2016 Mar.
Gomez-Simmonds A, Hu Y, Sullivan SB, Wang Z, Whittier S, Uhlemann AC. Evidence from a New York City hospital of rising incidence of genetically diverse carbapenem-resistant Enterobacter cloacae and dominance of ST171, 2007 – 2014. J Antimicrob Chemother 2016; 71(8):2351-3.
Pereira MR, Uhlemann AC. The evolving threat of carbapenem-resistant infections after liver transplantation: The case of Acinetobacter baumannii. Liver Transpl. 2016 May;22(5):579-81.
Gomez-Simmonds A, Greenman M, Sullivan SB, Tanner JP, Sowash MG, Whittier S, Uhlemann AC. Population structure of Klebsiella pneumoniae causing bloodstream infections at a New York City tertiary care hospital: diversification of multidrug-resistant isolates. J Clin Microbiol 2015 Jul;53(7):2060-7.
Uhlemann AC, Dordel J, Knox JR, Raven K, Parkhill J, Holden MT, Peacock SJ, Lowy FD. Molecular tracing of the emergence, diversification and transmission of S. aureus sequence type 8 in a New York community. Proc Natl Acad Sci U S A 2014; 111(18):6738-43.
Sowash MG, Uhlemann AC. Community-associated methicillin-resistant Staphylococcus aureus case studies. Methods Mol Biol. 2014;1085:25-69. Review.
Uhlemann AC, Hafer C, Miko BA, Sowash MG, Sullivan SB, Shu Q, Lowy FD. Emergence of sequence type 398 as a community- and healthcare-associated methicillin-susceptible Staphylococcus aureus in Northern Manhattan. Clin Infect Dis 2013; 57:700-3.
Uhlemann AC, Porcella SF, Trivedi S, Sullivan SB, Hafer C, Kennedy AD, Barbian KD, McCarthy AJ, Street C, Hirschberg DL, Lipkin WI, Lindsay JA, DeLeo FR, Lowy FD. Identification of a highly transmissible animal-independent Staphylococcus aureus ST398 clone with distinct genomic and cell adhesion properties. mBio 2012; 3: e00027-12.
Uhlemann AC, Kennedy AD, Martens C, Porcella SF, Deleo FR, Lowy FD. Toward an understanding of the evolution of Staphylococcus aureus strain USA300 during colonization in community households. Genome Biol Evol 2012; 4:1275-85.
Hafer C, Lin Y, Kornblum J, Lowy FD, Uhlemann AC. Contribution of selected gene mutations to resistance in clinical isolates of vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 2012; 56:5845-51.
Uhlemann AC, Fidock DA. Loss of malarial susceptibility to artemisinin in Thailand. Lancet 2012 379(9830):1928-30.
For a complete list of publications, please visit PubMed.gov